Diosmetin - 半岛电竞官方网址

Molecular Weight (MW)	300.26
Formula	C16H12O6
CAS No.	520-34-3
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility(In vitro)	DMSO: 60 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility(In vivo)	Chemical Name: 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one InChi Key: MBNGWHIJMBWFHU-UHFFFAOYSA-N InChi Code: InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3 SMILES Code: O=C1C=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13
Synonyms	Luteolin 4-methyl ether; HSDB-8101; Diosmetin; HSDB 8101; HSDB 8101; Luteolin 4'-methyl ether

Molecular Weight (MW)

300.26

Formula

C16H12O6

CAS No.

520-34-3

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility(In vitro)

DMSO: 60 mg/mL (199.8 mM)

Water: <1 mg/mL

Ethanol: <1 mg/mL

Solubility(In vivo)

Chemical Name: 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one

InChi Key: MBNGWHIJMBWFHU-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3

SMILES Code: O=C1C=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13

Synonyms

Luteolin 4-methyl ether; HSDB-8101; Diosmetin; HSDB 8101; HSDB 8101; Luteolin 4'-methyl ether

In Vitro	In vitroactivity: Diosmetin inhibits 3H-dopamine uptake in neuroblastoma cells, as well as in small-cell lung carcinoma cells, which is be responsible for the increased vascular tone observed in vivo after treatment with Diosmetin. Moreover, Diosmetin also removes iron from iron-loaded hepatocytes revealed a good relationship between this iron-chelating ability and the cytoprotective effect. Other studies proves that Diosmetin is a cytochrome P450 inhibitor, thus inhibiting carcinogen activation and and causing pharmacokinetic interactions with co-administered drugs metabolized. Cell Assay: In MCF-7 cells, at 24 h after the incubation of diosmetin, CYP1A1 mRNA was increased in a dose-dependent manner. In MCF-7 cells, diosmetin at 2.5 μM modestly increased CYP1A1 enzyme activity, with an activity increase in cells, while diosmetin at 5 μM did not increase the enzyme activity compared to controls in cells. Compared with controls, diosmetin dose-dependently increased the capacity of nuclear extracts to bind an oligonucleotide containing the AhR-binding sequence of CYP1A1.
In Vivo	Pretreatment with diosmetin significantly reduces serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-κB activation in cerulein-induced acute pancreatitis.
Animal model	Mice: Experimental acute pancreatitis is induced in mice by seven intraperitoneal injection of cerulein (50 μg/kg) at hourly intervals. Diosmetin (100 mg/kg) or vehicle is pretreated 2 h before the first cerulein injection. After 6 h, 9 h, 12 h of the first cerulein injection, the severity of acute pancreatitis is evaluated biochemically and morphologically
Formulation & Dosage	100 mg/kg
References	Pharmacol Res. 1992 Dec;26(4):395-402; Cancer Res. 1998 Jul 1;58(13):2754-60.

In Vitro

In vitroactivity: Diosmetin inhibits 3H-dopamine uptake in neuroblastoma cells, as well as in small-cell lung carcinoma cells, which is be responsible for the increased vascular tone observed in vivo after treatment with Diosmetin. Moreover, Diosmetin also removes iron from iron-loaded hepatocytes revealed a good relationship between this iron-chelating ability and the cytoprotective effect. Other studies proves that Diosmetin is a cytochrome P450 inhibitor, thus inhibiting carcinogen activation and and causing pharmacokinetic interactions with co-administered drugs metabolized.

Cell Assay: In MCF-7 cells, at 24 h after the incubation of diosmetin, CYP1A1 mRNA was increased in a dose-dependent manner. In MCF-7 cells, diosmetin at 2.5 μM modestly increased CYP1A1 enzyme activity, with an activity increase in cells, while diosmetin at 5 μM did not increase the enzyme activity compared to controls in cells. Compared with controls, diosmetin dose-dependently increased the capacity of nuclear extracts to bind an oligonucleotide containing the AhR-binding sequence of CYP1A1.

In Vivo

Pretreatment with diosmetin significantly reduces serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-κB activation in cerulein-induced acute pancreatitis.

Animal model

Mice: Experimental acute pancreatitis is induced in mice by seven intraperitoneal injection of cerulein (50 μg/kg) at hourly intervals. Diosmetin (100 mg/kg) or vehicle is pretreated 2 h before the first cerulein injection. After 6 h, 9 h, 12 h of the first cerulein injection, the severity of acute pancreatitis is evaluated biochemically and morphologically

Formulation & Dosage

100 mg/kg

References

Pharmacol Res. 1992 Dec;26(4):395-402; Cancer Res. 1998 Jul 1;58(13):2754-60.

CAS NO:	520-34-3
规格:	≥98%

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议
1g	电议
2g	电议
5g	电议